225 related articles for article (PubMed ID: 27991698)
1. A CD13-targeting peptide integrated protein inhibits human liver cancer growth by killing cancer stem cells and suppressing angiogenesis.
Zheng YB; Gong JH; Liu XJ; Li Y; Zhen YS
Mol Carcinog; 2017 May; 56(5):1395-1404. PubMed ID: 27991698
[TBL] [Abstract][Full Text] [Related]
2. An NGR-integrated and enediyne-energized apoprotein shows CD13-targeting antitumor activity.
Zheng YB; Shang BY; Li Y; Zhen YS
Biomed Pharmacother; 2013 Mar; 67(2):164-71. PubMed ID: 23206754
[TBL] [Abstract][Full Text] [Related]
3. An EGFR/CD13 bispecific fusion protein and its enediyne-energized analog show potent antitumor activity.
Sheng W; Shang Y; Li L; Zhen Y
Anticancer Drugs; 2014 Jan; 25(1):82-91. PubMed ID: 24100279
[TBL] [Abstract][Full Text] [Related]
4. The recombinant EGFR/CD13 bi-targeted fusion protein induces apoptosis and blocks tube formation.
Sheng W; Gong J; Jiang M; Zhen Y
Oncol Rep; 2017 Dec; 38(6):3507-3514. PubMed ID: 29130101
[TBL] [Abstract][Full Text] [Related]
5. A bispecific enediyne-energized fusion protein containing ligand-based and antibody-based oligopeptides against epidermal growth factor receptor and human epidermal growth factor receptor 2 shows potent antitumor activity.
Guo XF; Zhu XF; Shang Y; Zhang SH; Zhen YS
Clin Cancer Res; 2010 Apr; 16(7):2085-94. PubMed ID: 20332319
[TBL] [Abstract][Full Text] [Related]
6. A bispecific fusion protein and a bifunctional enediyne-energized fusion protein consisting of TRAIL, EGFR peptide ligand, and apoprotein of lidamycin against EGFR and DR4/5 show potent antitumor activity.
Zhu D; Wang X; Shang Y; Li Y; Jiang W; Li L; Chen SZ
Anticancer Drugs; 2015 Jan; 26(1):64-73. PubMed ID: 25122444
[TBL] [Abstract][Full Text] [Related]
7. Factor VII light chain-targeted lidamycin targets tissue factor-overexpressing tumor cells for cancer therapy.
Zhang Q; Liu XJ; Hu L; Liao DS; Zheng YB; Zhen YS; Song X
Int J Mol Med; 2012 Mar; 29(3):409-15. PubMed ID: 22108624
[TBL] [Abstract][Full Text] [Related]
8. An enediyne-energized single-domain antibody-containing fusion protein shows potent antitumor activity.
Miao QF; Liu XY; Shang BY; Ouyang ZG; Zhen YS
Anticancer Drugs; 2007 Feb; 18(2):127-37. PubMed ID: 17159599
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activities of dFv-LDP-AE: An enediyne-energized fusion protein targeting tumor-associated antigen gelatinases.
Zhong GS; Wu MN; Guo XF; Zhang SH; Miao QF; Zhen YS
Oncol Rep; 2012 Oct; 28(4):1193-9. PubMed ID: 22797730
[TBL] [Abstract][Full Text] [Related]
10. Generation and antitumor effects of an engineered and energized fusion protein VL-LDP-AE composed of single-domain antibody and lidamycin.
Miao Q; Shang B; Ouyang Z; Liu X; Zhen Y
Sci China C Life Sci; 2007 Aug; 50(4):447-56. PubMed ID: 17653664
[TBL] [Abstract][Full Text] [Related]
11. Factor VII light chain-targeted lidamycin shows intensified therapeutic efficacy for liver cancer.
Zhang Q; Liu X; Xu S; Li C; Zhang Y; Yang J; Zheng J
Cancer Biother Radiopharm; 2012 Aug; 27(6):384-91. PubMed ID: 22651685
[TBL] [Abstract][Full Text] [Related]
12. A bispecific enediyne-energized fusion protein targeting both epidermal growth factor receptor and insulin-like growth factor 1 receptor showing enhanced antitumor efficacy against non-small cell lung cancer.
Guo XF; Zhu XF; Cao HY; Zhong GS; Li L; Deng BG; Chen P; Wang PZ; Miao QF; Zhen YS
Oncotarget; 2017 Apr; 8(16):27286-27299. PubMed ID: 28460483
[TBL] [Abstract][Full Text] [Related]
13. NGR (Asn-Gly-Arg)-targeted delivery of coagulase to tumor vasculature arrests cancer cell growth.
Seidi K; Jahanban-Esfahlan R; Monhemi H; Zare P; Minofar B; Daei Farshchi Adli A; Farajzadeh D; Behzadi R; Mesgari Abbasi M; Neubauer HA; Moriggl R; Zarghami N; Javaheri T
Oncogene; 2018 Jul; 37(29):3967-3980. PubMed ID: 29662195
[TBL] [Abstract][Full Text] [Related]
14. An EGFR/HER2-Bispecific and enediyne-energized fusion protein shows high efficacy against esophageal cancer.
Guo XF; Zhu XF; Yang WC; Zhang SH; Zhen YS
PLoS One; 2014; 9(3):e92986. PubMed ID: 24664246
[TBL] [Abstract][Full Text] [Related]
15. Genetically engineered endostatin-lidamycin fusion proteins effectively inhibit tumor growth and metastasis.
Jiang WG; Lu XA; Shang BY; Fu Y; Zhang SH; Zhou D; Li L; Li Y; Luo Y; Zhen YS
BMC Cancer; 2013 Oct; 13():479. PubMed ID: 24128285
[TBL] [Abstract][Full Text] [Related]
16. Recombinant EGFR/MMP-2 bi-targeted fusion protein markedly binding to non-small-cell lung carcinoma and exerting potent therapeutic efficacy.
Xu J; Du Y; Liu XJ; Zhu BY; Zhang SH; Li L; Li Y; Wang XF; Shan CK; Wang RQ; Zhen YS
Pharmacol Res; 2017 Dec; 126():66-76. PubMed ID: 28392461
[TBL] [Abstract][Full Text] [Related]
17. Addition of an aminopeptidase N-binding sequence to human endostatin improves inhibition of ovarian carcinoma growth.
Yokoyama Y; Ramakrishnan S
Cancer; 2005 Jul; 104(2):321-31. PubMed ID: 15952188
[TBL] [Abstract][Full Text] [Related]
18. An antimicrobial peptide containing NGR motif has potent antitumor activity against CD13+ and CD13- tumor cells.
Zhang Z; Hou L; Feng L; Huang S; Luo M; Shao S; Zhang X; Gu S; Zhao X
Tumour Biol; 2015 Sep; 36(10):8167-75. PubMed ID: 25990455
[TBL] [Abstract][Full Text] [Related]
19. A cell penetrating peptide-integrated and enediyne-energized fusion protein shows potent antitumor activity.
Ru Q; Shang BY; Miao QF; Li L; Wu SY; Gao RJ; Zhen YS
Eur J Pharm Sci; 2012 Nov; 47(4):781-9. PubMed ID: 22982402
[TBL] [Abstract][Full Text] [Related]
20. Radiation synergizes with antitumor activity of CD13-targeted tissue factor in a HT1080 xenograft model of human soft tissue sarcoma.
Brand C; Greve B; Bölling T; Eich HT; Willich N; Harrach S; Hintelmann H; Lenz G; Mesters RM; Kessler T; Schliemann C; Berdel WE; Schwöppe C
PLoS One; 2020; 15(2):e0229271. PubMed ID: 32084238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
